[go: up one dir, main page]

AR032279A1 - METHOD FOR INHIBITING ONE OR MORE ACTIVITIES OF PROTEINIC KINASE, COMPOSED OF 2 - PIRAZOLIN-5-ONA PROTEINIC QUINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT - Google Patents

METHOD FOR INHIBITING ONE OR MORE ACTIVITIES OF PROTEINIC KINASE, COMPOSED OF 2 - PIRAZOLIN-5-ONA PROTEINIC QUINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT

Info

Publication number
AR032279A1
AR032279A1 ARP000103955A ARP000103955A AR032279A1 AR 032279 A1 AR032279 A1 AR 032279A1 AR P000103955 A ARP000103955 A AR P000103955A AR P000103955 A ARP000103955 A AR P000103955A AR 032279 A1 AR032279 A1 AR 032279A1
Authority
AR
Argentina
Prior art keywords
group
proteinic
cycloalkyl
inhibiting
pharmaceutical composition
Prior art date
Application number
ARP000103955A
Other languages
Spanish (es)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR032279A1 publication Critical patent/AR032279A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para inhibir una o más actividades de quinasa proteínica que comprende la administracion de un compuesto de 2-pirazolin-5-ona representado por al formula (1) y sales fisiologicamente aceptables y metabolitos biologicamente activos del mismo, en donde R se selecciona del grupo un grupo sustituido o sin sustituir que consiste de: grupo alifático, aromático, un grupo cicloalquilo (C3-6), un grupo heterocíclico, un grupo aralquilo, un grupo cicloalquil-alquilo (C3-6) y un grupo del heterociclil-alquilo; R1 es hidrogeno o -A-Z; R2 es hidrogeno o se selecciona del grupo sustituido o sin sustituir que consiste de: grupo alquilo inferior, un grupo aromático, un grupo cicloalquilo (C3-6), un grupo heterocíclico, un grupo aralquilo, un grupo cicloalquil-alquilo (C3-6), y un grupo heterociclil-alquilo; en donde A y Z son como se describen en la memoria. Un compuesto de 2-pirazolin-5-ona representado por la formula (2) y sales fisiologicamente aceptables del mismo, en donde R se selecciona del grupo sustituido o sin sustituir que consiste de: indol, imidazol, 1,2,3-triazol, 1,2,4-triazol, benzimidazol, 4,5,6,7-tetrahidroindol, benzoindol, azaindol, indazol, piridina, quinolina, pirimidina, benceno, pirazina, pirrol, pirazol, oxazol y tiazol; R1 es hidrogeno o -A-Z-; en donde A y Z son como se describen en la memoria. Una composicion farmacéutica que comprende el compuesto descripto y un vehículo o diluyente farmacéuticamente aceptable.A method for inhibiting one or more protein kinase activities comprising the administration of a 2-pyrazolin-5-one compound represented by formula (1) and physiologically acceptable salts and biologically active metabolites thereof, wherein R is selected from group a substituted or unsubstituted group consisting of: aliphatic, aromatic group, a cycloalkyl (C3-6) group, a heterocyclic group, an aralkyl group, a cycloalkyl-alkyl (C3-6) group and a heterocyclyl-alkyl group ; R1 is hydrogen or -A-Z; R2 is hydrogen or is selected from the substituted or unsubstituted group consisting of: lower alkyl group, an aromatic group, a cycloalkyl (C3-6) group, a heterocyclic group, an aralkyl group, a cycloalkyl-C3-6 alkyl group ), and a heterocyclyl-alkyl group; where A and Z are as described in memory. A 2-pyrazolin-5-one compound represented by formula (2) and physiologically acceptable salts thereof, wherein R is selected from the substituted or unsubstituted group consisting of: indole, imidazole, 1,2,3-triazole , 1,2,4-triazole, benzimidazole, 4,5,6,7-tetrahydroindole, benzoindole, azaindole, indazole, pyridine, quinoline, pyrimidine, benzene, pyrazine, pyrrole, pyrazole, oxazole and thiazole; R1 is hydrogen or -A-Z-; where A and Z are as described in memory. A pharmaceutical composition comprising the described compound and a pharmaceutically acceptable carrier or diluent.

ARP000103955A 1999-07-30 2000-07-31 METHOD FOR INHIBITING ONE OR MORE ACTIVITIES OF PROTEINIC KINASE, COMPOSED OF 2 - PIRAZOLIN-5-ONA PROTEINIC QUINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AR032279A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14656399P 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
AR032279A1 true AR032279A1 (en) 2003-11-05

Family

ID=22517965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103955A AR032279A1 (en) 1999-07-30 2000-07-31 METHOD FOR INHIBITING ONE OR MORE ACTIVITIES OF PROTEINIC KINASE, COMPOSED OF 2 - PIRAZOLIN-5-ONA PROTEINIC QUINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT

Country Status (21)

Country Link
EP (1) EP1218373A2 (en)
JP (1) JP2003506368A (en)
KR (1) KR20020091829A (en)
CN (1) CN1193026C (en)
AR (1) AR032279A1 (en)
AU (1) AU6388900A (en)
BG (1) BG106392A (en)
BR (1) BR0012896A (en)
CA (1) CA2380644A1 (en)
CZ (1) CZ2002302A3 (en)
HK (1) HK1049154A1 (en)
HU (1) HUP0400540A3 (en)
IL (1) IL147757A0 (en)
MX (1) MXPA02001088A (en)
NO (1) NO20020487L (en)
NZ (1) NZ516850A (en)
PL (1) PL354144A1 (en)
SK (1) SK1512002A3 (en)
TR (1) TR200200928T2 (en)
WO (1) WO2001009121A2 (en)
ZA (1) ZA200200477B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2003011287A1 (en) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
WO2005012255A1 (en) * 2003-08-01 2005-02-10 Mitsubishi Pharma Corporation Remedy for inflammatory joint diseases
EP1681063A4 (en) * 2003-10-14 2009-08-05 Satoshi Takeo AGENT FOR ATTENUATING MENTAL DISORDERS
JP5138938B2 (en) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Compounds and methods for the development of RET modulators
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129583A1 (en) * 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. Pyrazolone derivative
EP1900728A1 (en) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE102005057924A1 (en) * 2005-12-05 2007-06-06 Merck Patent Gmbh pyridazinone derivatives
BRPI0619563A2 (en) 2005-12-09 2011-10-04 Pharmasset Inc antiviral nucleosides
PT2084174E (en) 2006-10-10 2013-10-08 Hoffmann La Roche Preparation of nucleosides ribofuranosyl pyrimidines
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR100987557B1 (en) * 2008-03-18 2010-10-12 이화여자대학교 산학협력단 Compositions for treating or preventing vascular restenosis
US9145424B2 (en) 2008-11-20 2015-09-29 Northwestern University Treatment of amyotrophic lateral sclerosis
EP2367798B1 (en) * 2008-11-20 2018-02-28 Northwestern University Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
CN102361870B (en) 2009-04-03 2015-11-25 豪夫迈罗氏公司 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}- Amide compositions and uses thereof
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
MX2012005284A (en) 2009-11-06 2012-06-28 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
PT3290428T (en) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
JP5941069B2 (en) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for kinase regulation and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014017802A1 (en) 2012-07-23 2014-01-30 주식회사 유한양행 Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same
BR112016017781A2 (en) 2014-02-14 2017-08-08 Inception 2 Inc PYRAZOLONE COMPOUNDS AND USES THEREOF
CN105037269B (en) * 2015-07-10 2018-01-19 中国人民解放军第二军医大学 Substituted pyrazolecarboxylic ketone secretory protease inhibitors and preparation method thereof
ES2966825T3 (en) 2017-08-15 2024-04-24 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in the treatment of blood disorders
KR102625224B1 (en) * 2018-10-31 2024-01-15 주식회사 큐로젠 Composition for preventing, improving or treating autoimmune diseases comprising pyrazol-one derivatives
CN111793032B (en) * 2019-04-08 2021-11-19 四川省中医药科学院 Pyrazolone compounds and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369310A (en) * 1979-11-19 1983-01-18 Ciba-Geigy Ltd. Bleachable dyes
JPH078851B2 (en) * 1985-07-29 1995-02-01 鐘淵化学工業株式会社 3-phenylthiomethylstyrene derivative
JPS6229570A (en) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5-diisopropylbenzylidene heterocyclic compound
JP2678822B2 (en) * 1990-06-04 1997-11-19 富士写真フイルム株式会社 Silver halide photographic material

Also Published As

Publication number Publication date
NO20020487D0 (en) 2002-01-30
JP2003506368A (en) 2003-02-18
HK1049154A1 (en) 2003-05-02
EP1218373A2 (en) 2002-07-03
TR200200928T2 (en) 2002-09-23
HUP0400540A2 (en) 2004-06-28
HUP0400540A3 (en) 2004-09-28
BG106392A (en) 2002-12-29
WO2001009121A2 (en) 2001-02-08
WO2001009121A3 (en) 2002-05-02
CN1193026C (en) 2005-03-16
AU6388900A (en) 2001-02-19
IL147757A0 (en) 2002-08-14
BR0012896A (en) 2002-06-18
CA2380644A1 (en) 2001-02-08
NO20020487L (en) 2002-03-12
MXPA02001088A (en) 2003-09-22
CZ2002302A3 (en) 2002-06-12
SK1512002A3 (en) 2002-11-06
NZ516850A (en) 2004-09-24
CN1377346A (en) 2002-10-30
PL354144A1 (en) 2003-12-29
KR20020091829A (en) 2002-12-06
ZA200200477B (en) 2003-06-25

Similar Documents

Publication Publication Date Title
AR032279A1 (en) METHOD FOR INHIBITING ONE OR MORE ACTIVITIES OF PROTEINIC KINASE, COMPOSED OF 2 - PIRAZOLIN-5-ONA PROTEINIC QUINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
UY24434A1 (en) NEW IMIDAZOLES REPLACED WITH CYCLOALKYL
JP5559701B2 (en) Methods of treating fibrosis and cancer with imidazolium and imidazolinium compounds
TWI226329B (en) Compounds of the formula I for the treatment of ischemia, and pharmaceutical composition comprising the same
RU2337909C2 (en) Substituted indoles and pharmaceutical composition, possessing agonistic activity with respect to alfa- 1a/l adrenorecerptor
DE68907921D1 (en) SUBSTITUTED PYRROL, PYRAZOLE AND TRIAZOLE ANGIOTENSIN II ANTAGONISTS.
DE60103147D1 (en) 1,1-DIOXOISOTHIAZOLIDINE-SUBSTITUTED INDAZOLES AS INHIBITORS OF CELL PROLIFERATION
NO986087L (en) Oral preparation comprising an antifungal triazole compound
AR041262A1 (en) METHODS TO TREAT DRY EYE DISORDERS
NZ597647A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
RU2009128966A (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLR1 INHIBITORS
CA2509982A1 (en) N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
AU2005237788A1 (en) Indole and azaindole derivatives with antitumor action
EA200000488A1 (en) REPLACEMENT OF KATEHIN ON INDOZOL BIOISOSTER IN THERAPEUTICALLY ACTIVE COMPOUNDS
NO177006B (en) Analogous Process for the Preparation of Therapeutically Active 2-R2-R4-Substituted-3-R3-CO-1 - [(C-Associated-N-hetryl) - (Alk) N
YU173791A (en) INDOL AND BENZIMIDAZOLE-SUBSTITUTED IMIDAZOLE AND BENZIMIDAZOLE DERIVATIVES
PE20081850A1 (en) CYCLIZED DERIVATIVES AS EG-5 INHIBITORS
CZ92696A3 (en) Tetrahydropyridine or (4-hydroxypiperidine)alkylazoles having affinity for sigma and/or 5ht1a receptors
CN101272782A (en) Novel triazole derivatives as ghrelin analog ligands for growth hormone secretagogue receptors
RU2403250C2 (en) Pyperidin-4-ylamide derivatives and their application as antagonists of sst receptor subtupe 5
ATE246684T1 (en) SUBSTITUTED 1,4-DIHYDROINDENO(1,2-C)PYRAZOLES AS INHIBITORS OF TYROSINE KINASE
Chevula et al. Design, synthesis, and screening for anticancer and antimicrobial activities of new dihydropyridine‐anchored pyrazole and 1, 2, 3‐triazole hybrids
Ouvry et al. Discovery and characterization of CD12681, a potent RORγ inverse agonist, preclinical candidate for the topical treatment of psoriasis
JP2006516604A (en) 5HT7 antagonists and inverse agonists
ES8407488A1 (en) A PROCEDURE FOR THE PREPARATION OF NEW TRIAZOL DERIVATIVES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure